AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05276336
Drug: Pharmacology treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be treated with intranasal steroid and AH-1 according to ARIA WHO guideline 2008. Fluticasone furoate will be given twice a day with two sprays (100 µg) for each nostril for 2 weeks, then continue for once a day with two sprays (100 µg). Antihistamine H-1 is given 10 mg, once a day. Pharmacology treatment is given for 4 weeks, then intranasal steroid will be continued for another 4 weeks.
Trial: NCT00699946
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo administered preoperatively and postoperatively prior to discharge to inpatient nursing floor
Trial: NCT02410382
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral placebo
Trial: NCT02507661
Drug: preservation of alveolar ridge with beta tricalcium phosphate + collagen - 2 months
RxNorm normalized name: tricalcium phosphate
DrugBank: Calcium citrate (DB11093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02507661
Drug: no-preservation of alveolar ridge - 2 months
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02507661
Drug: preservation of alveolar ridge with beta tricalcium phosphate + collagen - 4 months
RxNorm normalized name: tricalcium phosphate
DrugBank: Calcium citrate (DB11093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02507661
Drug: no-preservation of alveolar ridge - 4 months
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02507661
Drug: no-preservation of alveolar ridge - 9 months
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01067118
Drug: LINjeta U-100 Insulin
RxNorm normalized name: insulin isophane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LINjeta U-100 Insulin will be used per the subjects normal insulin carbohydrate and insulin sensitivity factors
Trial: NCT03943576
Drug: GXCPC1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The dose regimen is one single intra-articular injection of GXCPC1 containing 6.7×10\^6 or 4×10\^7 ADSCs in 3 mL saline. (allogeneic injection)
Trial: NCT00634140
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo for 4-6 weeks
Trial: NCT02796833
Drug: SMOFlipid20%
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03346187
Drug: Test drug(CKD-337)
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CKD-337(Atorvastatin calcium trihydrate 20mg+choline fenofibrate 178.8mg/capsule)
Trial: NCT02807220
Drug: Imuneks 10mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two capsules of the study drug every morning approximately two hours after breakfast for six weeks
Trial: NCT02444507
Drug: Nexium powder for injection and infusion 40 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference Drug, Active substance: Esomeprazole 40 mg, Each single dose of esomeprazole 40 mg will be administrated as intravenous infusion over 30 minutes.
Trial: NCT02444507
Drug: Esomelone Powder for Solution for Injection / Infusion 40 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test Drug, Active substance: Esomeprazole 40 mg, Each single dose of esomeprazole 40 mg will be administrated as intravenous infusion over 30 minutes.
Trial: NCT03953677
Drug: 5% glucose Infusion solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of placebo (5% glucose) at 0.7 µg/kg/h for 2 hours and then 1 µg/kg/h at fixed dose
Trial: NCT02836899
Drug: Nitric Oxide
RxNorm normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhaled nitric oxide will be administered in a final concentration of 80 ppm. The treatment will begin at the onset of the cardiopulmonary bypass until to 24h after Intensive Care Unit (ICU) admission, including 2-4 hours of weaning from nitric oxide and careful hemodynamics monitoring.
Trial: NCT02253082
Drug: OctaplasLG®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OctaplasLG® is an industrial donor plasma product pooled from approximately 400 single donor units. It possess' unique features when compared to standard FFP, such as having standardized concentrations of natural pro- and anti-coagulation factors, standardized volume and as being pathogen free. Very importantly, the manufacturing method of OctaplasLG® removes immune complexes and cells in several steps of microfiltration in addition to viral, bacterial and prion pathogen inactivation.
Trial: NCT01166789
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 capsules daily, taken in morning and evening
Trial: NCT02253095
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00361972
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo comparator to lansoprazole 30 mg, twice daily for 6 weeks
Trial: NCT00786305
Drug: ceftazidime and amikacin
RxNorm normalized name: Amikacin
DrugBank: Amikacin (DB00479)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Nebulized ceftazidime 15 mg/kg/3h during 8 days and nebulized amikacin 25 mg/kg/day during 3 days
Trial: NCT00786305
Drug: ceftazidime and amikacin
RxNorm normalized name: Amikacin
DrugBank: Amikacin (DB00479)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous infusion of ceftazidime 30 mg/kg over 30 min followed by continuous infusion 90 mg/kg/day during 8 days and intravenous infusion of amikacin 15 mg/kg/day over 30 min during 3 days
Trial: NCT06192472
Drug: 3% Polidcanol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3% Polidcanol
Trial: NCT03815630
Drug: pd-1 and dc-cik cells
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total dose of 10ml Keytruda will be administered at day0, 60million DC cells and 1.5 billion CIK at day1, 1.5 billion CIK cells at day2, 1.5 billion CIK cells at day3 .
Trial: NCT03768089
Drug: TEZ/IVA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose combination tablet for oral administration.
Trial: NCT03768089
Drug: Placebo (matched to TEZ/IVA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matched to TEZ/IVA for oral administration.
Trial: NCT03768089
Drug: Placebo (matched to IVA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matched to IVA for oral administration.
Trial: NCT01534286
Drug: Theramine
RxNorm normalized name: Theramine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theramine 2 capsules 3 times per day
Trial: NCT01534286
Drug: Theramine- like placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theramine-like placebo capsules 2 three times daily
Trial: NCT00480831
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous repeating dose
Trial: NCT00480831
Drug: PRO95780
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous repeating dose
Trial: NCT00003776
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00003776
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00003776
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00657137
Drug: apricoxib + lapatinib + capecitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: apricoxib: 100 mg tablets, 400 mg/day~lapatinib: per package insert~capecitabine: per package insert
Trial: NCT00657137
Drug: placebo + lapatinib + capecitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo: 100 mg tablets, 400 mg/day~lapatinib: per package insert~capecitabine: per package insert
Trial: NCT03686930
Drug: Placebo (for FP-045 oral solution)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants (cohorts 1-3) will receive FP-045 oral solution matching placebo.
Trial: NCT01565408
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple subcutaneous (s.c., under the skin) doses administered every second week for six weeks.
Trial: NCT04364815
Drug: Placebo plus standard preventive measures
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet plus standard preventive measures as defined by PGH-HICU
Trial: NCT01637584
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The medication will be administered in the same manner, regardless of active or placebo, as the study physician and investigators, as well as the participants, will be blind to the type of medication they are taking.
Trial: NCT02988726
Drug: Antineoplaston therapy (Atengenal + Astugenal)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adults with a recurrent/residual Neurofibroma or Schwannoma will receive Antineoplaston therapy (Atengenal + Astugenal).
Trial: NCT03536325
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive matching placebo on Day 1.
Trial: NCT01721486
Drug: IV acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV acetaminophen 15 mg/kg (up to 1000 mg) over 15 minute infusion after IV placement in OR .
Trial: NCT01721486
Drug: PO acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PO acetaminophen elixir 15 mg/kg (up to 1000 mg) administered approximately 90 minutes (+/- 30minutes) prior to induction of anesthesia in the pre-operative area.
Trial: NCT02030769
Drug: Pronase
RxNorm normalized name: Pronase enzyme B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: use pronase to improve visibility during endoscopical iodine staining
Trial: NCT01501890
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% NaCl
Trial: NCT04149171
Drug: conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard treatment based on crystalloid fluid and tranexamic acid (TXA)
Trial: NCT02812238
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule daily for a period of 7 days in a double blinded fashion either from the start of tx or after 1 week of NR at a dose of 1000mg/day.
Trial: NCT00000553
Drug: simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000553
Drug: antioxidants
RxNorm normalized name: E Complex with Antioxidants
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02534883
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To be placed vaginally
Trial: NCT01223339
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets to Ertugliflozin administered in the fasted state
Trial: NCT01223339
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets administered once daily in the fed state for 7 days
Trial: NCT04303429
Drug: FOLFOX/XELOX/Capecitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients enrolled in the chemotherapy group will receive postoperative chemotherapy (investigator's choice) for 3 months or 6 months.
Trial: NCT01704508
Drug: Artemether-lumefantrine
RxNorm normalized name: artemether-lumefantrine
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03135912
Drug: Experimental Drug SESC 01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical experimental treatment comprising a combination of approved topical therapies and a new dosage method.
Trial: NCT03135912
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage method of SESC 01, without active ingredients.
Trial: NCT00092144
Drug: Comparator: placebo / Duration of Treatment: 4 weeks
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00651118
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT02025634
Drug: Intravenous Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants randomized to intravenous acetaminophen (Ofirmev) will receive an infusion of Ofirmev in 100 ml of 0.9 NS according to manufacturer's recommendations related to subject's weight.
Trial: NCT02025634
Drug: Placebo (0.9% Normal Saline infusion)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of 100 ml of 0.9% NS
Trial: NCT00649285
Drug: Macrobid® Capsules 100 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100mg, single dose fed
Trial: NCT01696799
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01844297
Drug: TDF+3TC+EFV
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04238091
Drug: Fecal material transfer therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fecal microbiota transplants will be performed as follows:~FMP Retention Enema: (FMP 250 mL) Dosage Form: Screened human donor stool, suspended in diluent of 12.5% glycerol and sterile normal saline buffer (0.9% NaCl) standardized to a 5X concentration (1g stool : 5mL diluent ratio), homogenized, filtered to 330 microns and aliquoted to sterile 250mL vessels.~Route of Administration: Fecal transplant will be performed under medical supervision. Lubricated enema tube will be inserted into rectum and contents expelled into the distal colon with the subject requested to retain material for a target dwell time of 3 to 24 hours with a mean target of 10 hours. Participants will lie in the left lateral decubitus position but if mobility permits will rotate to supine and right lateral decubitus position.~One half of study subjects will receive a 3 day course of antibiotics prior to fecal transplant, while the other half will not.
Trial: NCT04238091
Drug: Pre-FMT Antibiotic Cocktail
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For three days prior to the transplant, one half (20) of the subjects enrolled will be treated with antibiotics to reduce the burden of the existing microbiome. The antibiotic regimen will consist of: oral vancomycin 250 mg qid, ciprofloxacin 500 mg bid, and metronidazole 500 mg tid. For subjects who have antibiotic allergies, appropriate antibiotic substitutions will be made. Subjects will stop the antibiotics 48 hours before the fecal transplant.
Trial: NCT04238091
Drug: Bowel Prep
RxNorm normalized name: Suprep Bowel Prep Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The night before the transplant, all enrolled subjects will take 20 mg of bisacodyl and a large volume bowel preparation (GoLyteley 4000cc). Fecal transplant will be performed under medical supervision. After the transplant, subjects will take 4 mg of loperamide to increase transplant retention.
Trial: NCT03462641
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 cc normal saline
Trial: NCT02443337
Drug: LY3023414
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT00002509
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03849664
Drug: Cytoflavin® solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single drip infusion of 20 ml of Cytoflavin® solution in 200 ml of 0.9%NaCl intravenously once a day
Trial: NCT03849664
Drug: Cytoflavin® enteric-coated tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 tablets, orally, with 100 ml of drinking water, 30 minutes before meals, 2 times a day, with an interval of 8-10 hours (but no later than 18:00).
Trial: NCT03849664
Drug: Placebo solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single drip infusion of 20 ml of placebo solution in 200 ml of 0.9%NaCl intravenously once a day
Trial: NCT03849664
Drug: Placebo enteric-coated tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 tablets, orally, with 100 ml of drinking water, 30 minutes before meals, 2 times a day, with an interval of 8-10 hours (but no later than 18:00).
Trial: NCT02819297
Drug: BLI400 Laxative
RxNorm normalized name: LAXATIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 21 gm BLI400 powder
Trial: NCT02819297
Drug: BLI400 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Equivalent amount of placebo powder
Trial: NCT02317497
Drug: Vasopressors to maintain normal blood pressure values, if needed
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02317497
Drug: Osmotherapeutics to lowr intracranial pressure, if needed
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01927406
Drug: Prostaglandin Analog
RxNorm normalized name: Prostaglandin analog
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The first choice drug from group of Prostaglandin Analogues will be bimatoprost, if patient will suffer from any side effect of this drug another drug from this group will be administer. If patient turned out to cannot tolerate the prostaglandin analog therapy then the exclusion criteria will be met.
Trial: NCT01852942
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one tablet by mouth daily
Trial: NCT00308503
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration
Trial: NCT01772303
Drug: HO/03/03 10-40 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HO/03/03 10-40µg once daily (Topically) for up to 24 weeks.
Trial: NCT03679780
Drug: NG Nitro L Arginine Methyl Ester
RxNorm normalized name: methyl L-arginine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-Name is a NOS inhibitor that is administered to each site to allow for the quantification of NO contribution to vasodilation. The infusion rate will be 2 µl/min
Trial: NCT04283162
Drug: Calcium Dobesilate
RxNorm normalized name: CALCIUM DOBESILATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: use calcium dobesilate at the dosage of 500 mg, orally, 3 times per day, for 12 months
Trial: NCT00004733
Drug: levodopa
RxNorm normalized name: Levodopa
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT04001881
Drug: Spinal anesthesia
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal anesthesia is introduced with a single intrathecal injection of 12 to 18 mg (15 mg average dose) plain ropivacaine (0.75% solution) using a 22 or 25-gauge needle (pencil-point) with the patient in the lateral position.
Trial: NCT02232425
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04782856
Drug: Levothyroxine
RxNorm normalized name: Levothyroxine
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: levothyroxine sodium tablet for oral use
Trial: NCT04782856
Drug: Liothyronine
RxNorm normalized name: Liothyronine
DrugBank: Liothyronine (DB00279)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liothyronine sodium tablets for oral use treatment of hypothyroidism
Trial: NCT04782856
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: inert sugar tablets for oral use blinding for treatment of hypothyroidism
Trial: NCT00138944
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: od
Trial: NCT00138944
Drug: eplerenone
RxNorm normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50mg od
Trial: NCT03020823
Drug: SCB01A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intra-subject dose escalation, 12, 18, 24 mg/m2, 24h-IV infusion (in the vein) on day 1 and 8 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
Trial: NCT02631863
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with illumination
Trial: NCT03911440
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral doxycycline is given with a dosage of 2-4 mg/kg/day divided into twice a day for 5-10 days.
Trial: NCT03911440
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin is given with a dosage of 10 mg/kg/day once a day for 3 days.
Trial: NCT01591291
Drug: Placebo + Brief Behavioral Enhancement Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo twice daily
Trial: NCT02794896
Drug: High dose propofol, fentanyl and sevoflurane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deep Anesthesia
Trial: NCT02794896
Drug: Low dose propofol, fentanyl and sevoflurane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shallow Anesthesia
Trial: NCT01843166
Drug: Placebo cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2g at bedtime twice weekly
Trial: NCT03860428
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: In the medical treatment arm the in-tention is to close the ductus arteriosus.
Trial: NCT03715140
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02799758
Drug: Livalo® IR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Livalo® IR 4 mg daily for 52 weeks
Trial: NCT02799758
Drug: Placebo (for NK-104-CR)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NK-104-CR 8 mg placebo for 52 weeks
Trial: NCT00644969
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomization 2:1 treatment to placebo
Trial: NCT01020279
Drug: Celecoxib, Ketoprofen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoprofen in Transfersome® gel, 2 g gel on the calf, 4 g gel on the quadriceps, b.i.d.~Celecoxib, 200 mg, one capsule b.i.d.